Glossary
:
Legal/Privacy
:
Contact
Product Pipeline :
Vaccine Market
HIV
Hepatitis C
Influenza
Vaccine Market
Hepatitis B
Rotavirus
Mosquito diseases
Breast Cancer
Vaccine Market
The market for timely, low cost and accurate reactive or non-reactive
epitope
identification is extremely large. The vaccine market is viewed as the next mainstay of revenues for the major pharmaceutical companies, with revenues as large as that from other drug markets. Vaccines, unlike other drugs, have the benefit that the threat from generic competition is low. The global vaccine market is predicted to increase from US$10 billion (reported in 2005) to US$40 billion in 2015.
The other misconception is that the majority of vaccines are for the benefit of the third world, which would restrict revenues, however it is now widely acknowledged that 75% of all vaccines are for the western world.
The third benefit over other drugs is that vaccines have a greater chance of clinical success if the pre-clinical studies have been positive/successful.